Article first published online: 17 AUG 2007
Copyright © 2007 John Wiley & Sons, Ltd.
Managerial and Decision Economics
Special Issue: Economic and Policy Issues in the Pharmaceutical Industry
Volume 28, Issue 4-5, pages 285–291, June - August 2007
How to Cite
DiMasi, J. A. (2007), Commentary. Manage. Decis. Econ., 28: 285–291. doi: 10.1002/mde.1341
- Issue published online: 17 AUG 2007
- Article first published online: 17 AUG 2007
The three papers by Scherer (2007), Berndt et al. (2007), and Reiffen and Ward (2007) in this issue cover disparate topics, but together they manage to encompass much of what is important during a drug's lifecycle. Scherer's paper examines pharmaceutical industry R&D productivity and efficacy and safety testing during a new drug's development, Berndt, Danzon and Kruse investigate cross-national data on utilization, pricing, promotion, and diffusion of brand name drugs after they have been developed for marketing approval, and Reiffen and Ward explore generic competition once a new drug loses patent protection. They add much to our understanding of these topics. Copyright © 2007 John Wiley & Sons, Ltd.